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Ambulatory systolic blood pressure (BP) correlates better
with risk factors for progression of chronic kidney disease
(CKD) compared to clinic measured BP, but its role in
predicting end-stage renal disease (ESRD) and death in
patients with CKD is unknown. In a cohort study of 217
Veterans with CKD BP was measured by ambulatory
monitoring and in the clinic. Twenty-four hour ambulatory BP
was 133.5716.6/73.1711.1 mm Hg and clinic BP was
155.2725.6/84.7714.2 mm Hg. The composite renal end
point of ESRD or death over a median follow-up of 3.5 years
occurred in 75 patients (34.5%), death occurred in 52 patients
(24.0%), and ESRD in 36/178 patients (20.2%). Thirty-nine
patients died before reaching ESRD. One standard deviation
(s.d.) increase in systolic BP increased the risk of composite
outcome to 1.69 (95% confidence interval (CI) 1.32–2.17) for
standard clinic measurement and to 1.88 (95% CI 1.48–2.39)
for 24 h ambulatory BP recording. One s.d. increase in 24 h
ambulatory systolic BP increased the risk of ESRD to 3.04
(95% CI 2.13–4.35) and to 2.20 (95% CI 1.43–3.39) when
adjusted for standard clinic systolic BP. Non-dipping was
associated with increased risk of total mortality and
composite end point. In patients with CKD, BPs obtained by
ambulatory monitoring are a stronger predictor of ESRD or
death compared to BPs obtained in the clinic. Systolic
ambulatory BP and nondipping are independent predictors
for ESRD after adjusting for clinic BP. However, adjustment
for other risk factors for CKD progression removes the
independent prognostic value of ambulatory BP.
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Hypertension is seen in at least 70% of people with chronic
kidney disease (CKD) when measured using standard
methods.1 Although blood pressure (BP) control to o130/
80 mm Hg is currently the goal of antihypertensive therapy in
patients with CKD,2 this is only achieved in about 10% of the
patients.3 The importance of systolic BP reduction in patients
with CKD is underscored by the fact that each 10 mm Hg
increase in follow-up systolic BP confers a 35% increase in
risk of hospitalization for cardiovascular and cerebrovascular
disease.4 Thus, control of systolic BP in CKD is of urgent
importance.
We have recently shown that risk factors for progression of
kidney disease such as age, ethnicity, and proteinuria are also
strongly associated with systolic BP.5 This association of risk
factors for CKD progression with systolic hypertension is
stronger with ambulatory BP recordings rather than with
clinic BP recordings. Ambulatory BP monitoring allows
measurement of BP in the out-of-office setting.6 In patients
with essential hypertension, ambulatory BP monitoring
better predicts cardiovascular morbidity and mortality
compared to clinic-based recordings.7 From above considera-
tions, the obvious hypothesis that emerges is that ambulatory
BP monitoring would be more strongly associated with hard
outcomes in patients with CKD, such as end-stage renal
disease (ESRD) and death. Although ambulatory BP
monitoring is widely utilized, its role in predicting ‘hard’
renal end points such as ESRD and death is unknown. As
ambulatory BP recordings allow measurement of BP during
sleep, another purpose of this study was to evaluate the effect
of day and night BP as well as the impact of the fall in systolic
BP during night – the so-called dipping phenomenon – on
these outcomes.
RESULTS
Four hundred and twenty four patients were screened for the
study, of which 277 (65%) qualified. Twenty-seven patients
with stage 2 CKD but no microalbuminuria were excluded.
Of the remaining, 217 (78%) had adequate recordings of
ambulatory and clinic BPs and were the subject of further
analysis.
The baseline characteristics of these 217 subjects are
shown in Table 1. The older age and predominance of men is
consistent with the Veteran population.
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The median follow-up was 3.5 years (inter-quartile
range 2.9–3.9 years). During this follow-up period, 52
(24%) patients died and 75 (34.5%) had the combined
end point of ESRD or death. Thirty-nine patients died
before reaching ESRD; of the 178 remaining patients, 36
reached ESRD (20.2%). The crude mortality rate was 74.2/
1000 patient-years, ESRD rate was 62.6/1000 patient-years,
and the combined end-point rate was 116.7/1000 patient-
years.
Table 2 shows the results of the ESRD, death, or the
combined end point. Diastolic BPs, whether obtained by
ambulatory monitoring or in the clinic, were not useful in
predicting the composite end point. A low daytime
ambulatory BP was associated with increased hazard ratio
(HR) of death. Night ambulatory diastolic BPs and clinic
diastolic BPs were predictive of ESRD.
Systolic BP regardless of the technique was predictive of
the ESRD, death, or the combined end point. In unadjusted
analyses, each standard deviation (s.d.) increase in systolic BP
increased the HR of the combined end point 1.88 for 24 h
ambulatory BP, 1.77 for day ambulatory BP, 1.86 for night
ambulatory BP, and 1.69 for clinic BP. The magnitude of
increase in risk for ESRD was greater for 24 h ambulatory
systolic BP (HR 3.04) compared to clinic systolic BP (HR
2.75). Day ambulatory BP imparted a greater risk for ESRD
(HR 3.06) compared to night ambulatory BP (HR 2.53).
Diastolic BP elevation by 1 s.d. increased the HR for ESRD by
1.52 with night ambulatory BP and 1.42 for clinic diastolic
BP. Total mortality was increased 1.39 by 1 s.d. increase in
clinic BP and 1.43 by 24 h ambulatory systolic BP. Night
ambulatory BP imparted a greater risk of total mortality (HR
1.50) compared to day ambulatory BP (HR 1.32). Low day
diastolic BP increased total mortality.
Figure 1 shows that the relationship of ESRD to clinic BP
measurement is modified by 24 h ambulatory systolic BP.
Among patients with well-controlled clinic systolic BP
measurement, none had ESRD. In those patients who had
poor systolic BP control by clinic measurement, Figure 1
shows that 3/51 (6%) with good ambulatory systolic BP but
31/95 (33%) with poor 24 h ambulatory systolic BP reached
ESRD (Po0.05). Thus, ambulatory BP recordings could
further refine the prognosis in patients who apparently had
poor clinic BP control.
For each 1 s.d. increase in 24 h ambulatory systolic BP, the
HR of composite end point was increased 1.88, ESRD by
3.04, and total mortality by 1.43 (Table 3). Adjustments for
clinic systolic BP did not remove the statistical significance of
the results, except for total mortality. After adjustment for
clinic systolic BP, 1 s.d. (16.3 mm Hg) increase in 24 h
ambulatory systolic BP increased the HR of ESRD by 2.2-fold
and of the composite end point by 1.62. However,
adjustments for eight other risk factors for ESRD, age,
ethnicity, diabetes mellitus, log protein/creatinine ratio,
estimated glomerular filtration rate, serum albumin, hemo-
globin, and angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker use, removed the statistical
significance of the relationship between ambulatory BP and
outcomes.
The mean decline in sleeping systolic BP was
7.2711.8 mm Hg. One s.d. increase (11.8 mm Hg) in
Table 1 | Clinical characteristics of the study population
Clinical characteristics N=217
Age (years) 67.4 (10.9)
Men 209 (96.3%)
Ethnicity
White 172 (79.3%)
Black 44 (20.3%)
Other 1 (0.5%)
Weight (kg) 94 (24.3)
Height (inches) 69 (3.4)
Body mass index (kg/m2) 30.5 (6.8)
Alcohol user 42 (19.4%)
Smoking
Current 44 (20.3%)
Former 131 (60.4%)
Never 42 (19.4%)
Diabetes mellitus 91 (41.9%)
History of gout or active disease 42 (19.4%)
Coronary artery disease 83 (38.2%)
Cerebrovascular disease 29 (13.4%)
Peripheral vascular disease 42 (19.4%)
Etiology of chronic kidney disease
Diabetes mellitus 80 (36.9%)
Hypertension 115 (53.0%)
Glomerulonephritis 12 (5.6%)
Obstruction 6 (2.8%)
Other 4 (1.8%)
Number receiving antihypertensive drugs 199 (91.7%)
Angiotensin-converting enzyme inhibitors 104 (47.9%)
Angiotensin receptor blockers 41 (18.9%)
Serum cholesterol (mg/dl) 182 (37.0)
Serum albumin (g/dl) 3.8 (0.4)
Hemoglobin (g/dl) 13.2 (1.8)
Urine protein/creatinine (median;
inter-quartile range)
0.143 (0.073–0.787)
Blood urea nitrogen (mg/dl) 31.5 (17.5)
Serum creatinine (mg/dl) 2.0 (0.97)
Estimated glomerular filtration rate
(ml/min/1.73 m2)
44.8 (21.7)
Clinic blood pressure (mm Hg) 155.2 (25.6)/84.7 (14.2)
24 h ambulatory BP (mm Hg) 133.5 (16.6)/73.1 (11.1)
Day ambulatory BP (mm Hg) 135.1 (16.3)/74.7 (11.2)
Night ambulatory BP (mm Hg) 130.1 (19.7)/69.4 (12.0)
Awake ambulatory BP (mm Hg) 135.6 (16.2)/75.2 (11.1)
Asleep ambulatory BP (mm Hg) 128.4 (20.2)/68.4 (12.2)
Dipping (asleep minus awake
ambulatory systolic BP)
7.2 (11.8)
Dipping (night minus day
ambulatory systolic BP)
5.0 (10.9)
Dipping (asleep/awake ratio) 0.946 (0.085)
Dipping (night/day ratio) 0.963 (0.080)
Number dippers (asleep/awake ratio o0.9) 62 (29%)
Number dippers (night/day ratio o0.9) 43 (20%)
Values are means (s.d.) or numbers (%).
Bold numerals indicate those hazard ratios that were statistically significant.
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sleeping systolic BP increased the HR of death by 1.44 and
composite renal end point by 1.31 (Table 4). Similar results
were obtained when asleep/awake ratio, instead of the asleep
to awake difference, were used in the analyses. The use of
night/day ambulatory systolic BP ratio demonstrated an
increased HR of the composite outcome (1.52), ESRD (1.53),
and total mortality (1.54). Thus, the ratio of night/day
ambulatory systolic BP were further analyzed.
Table 5 shows that dipping – defined by the night/day ratio
– adjusted for 24 h ambulatory BP reduced the HR for
composite end point to 1.28 and death to 1.42, but removed
the statistical significance for ESRD risk prediction. Night
ambulatory BP was predictive of the composite end point,
ESRD, and total mortality, whereas day ambulatory BP was
not predictive of total mortality.
From the foregoing analyses, it appeared that day BP was
of greater importance in predicting ESRD, whereas night BP
was of greater importance in predicting death. When we
adjusted day BP for night BP, the statistical significance of
day BP remained for predicting ESRD, but was removed for
predicting death (Table 5). Conversely, when we adjusted
night BP for day BP, the statistical significance of night BP
remained for predicting death and the composite end point,
but was removed for predicting ESRD.
Figure 2 demonstrates that the tertiles of dipping based on
the night/day ratio are associated with increasing ESRD rates.
Those in the lowest tertiles had the least ESRD events compared
to those in the higher tertiles (P¼ 0.016, log-rank test).
Finally, 24 h ambulatory systolic BPs were divided into three
categories, o130, 130 to o160, and 160 mm Hg or more,
reflecting nationally recommended levels of control, and two
degrees of poor control.8 We found that 3/76 (4%) patients in
the well-controlled category had ESRD, 23/88 (26%) patients
in 130 to o160 mm Hg had ESRD, and 8/11 (73%) in the
160 mm Hg or more category had ESRD (Figure 3). The linear
trend between severity of hypertension and occurrence of
ESRD was significant by the log-rank test (Po0.0001).
DISCUSSION
The results of our prospective cohort study demonstrate that,
after adjustment for clinic BP, 24 h ambulatory systolic BP
provided additional prognostic information concerning
ESRD and the composite end point of ESRD and death.
Among the components of the end points that we studied,
the strongest relationship emerged between systolic BP and
ESRD compared to total mortality or the composite end
Table 2 | Hazard ratios associated with ambulatory and clinic BP monitoring
Systolic BP Diastolic BP
s.d. of systolic BP
(mm Hg)
Hazard
ratio
95% confidence
interval
s.d. of diastolic
BP (mm Hg)
Hazard
ratio
95% confidence
interval
End stage renal disease or death
24 h ambulatory BP 16.3 1.88 1.48–2.39 11.1 1.04 0.82–1.32
Day ambulatory BP 16.3 1.77 1.38–2.26 11.2 0.96 0.75–1.22
Night ambulatory BP 19.7 1.86 1.49–2.33 12 1.19 0.96–1.49
Clinic BP 25.6 1.69 1.32–2.17 14.2 0.91 0.80–1.28
End stage renal disease
24 h ambulatory BP 16.3 3.04 2.13–4.35 11.1 1.35 0.997–1.84
Day ambulatory BP 16.3 3.06 2.10–4.45 11.2 1.24 0.89–1.71
Night ambulatory BP 19.7 2.53 1.86–3.44 12 1.52 1.16–2.01
Clinic BP 25.6 2.75 1.87–4.04 14.2 1.42 1.03–1.97
Death
24 h ambulatory BP 16.3 1.43 1.08–1.90 11.1 0.75 0.55–1.03
Day ambulatory BP 16.3 1.32 0.98–1.76 11.2 0.69 0.50–0.95
Night ambulatory BP 19.7 1.5 1.15–1.96 12 0.9 0.67–1.21
Clinic BP 25.6 1.39 1.04–1.85 14.2 0.75 0.56–1.01
BP=blood pressure; s.d.=standard deviation.
Hazard ratios are reported for 1 s.d. change in systolic and diastolic BP.
Bold numerals indicate those hazard ratios that were statistically significant.
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Figure 1 | Cumulative risk of ESRD in patients with elevated
systolic clinic BP. None of the patients who had well-controlled
standardized clinic BP had ESRD. This figure shows that those with
well-controlled awake ambulatory BP (o130 mm Hg) but poorly
controlled standardized clinic BP (130 mm Hg or more) – white coat
hypertension – had fewer ESRD events (lower line) compared to those
with poorly controlled ambulatory BP (upper line) (Po0.05 by
log-rank test). Thus, poor control of awake ambulatory systolic BP
can improve the assessment of elevated clinic systolic BP.
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point. Whereas day ambulatory BP was a stronger predictor
of ESRD, night ambulatory BP was a stronger predictor of
total mortality and the composite renal end point. Dipping
added to the diagnostic importance of ambulatory BP
monitoring in predicting ESRD or deaths in our study, even
after adjusting for 24-h ambulatory systolic BP.
Although a similar study that links ambulatory BP to
ESRD outcome in non-dialysis CKD patients is not available
for comparison, the results of our study are consistent with
previously published cohort studies in the hypertensive
population without kidney disease examining the influence
of ambulatory BP with clinic BPs on total and cardiovascular
mortality and cardiovascular morbidity.9,10
Non-dipping has been associated with greater prevalence
of left ventricular hypertrophy11 and poorer cardiovascular
Table 3 | Hazard ratios for renal end points associated with 24 h ambulatory systolic BP
ESRD or death ESRD Total mortality
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Unadjusted 1.88 1.48–2.39 3.04 2.13–4.35 1.43 1.08–1.90
Adjusted for clinic systolic BP 1.62 1.21–2.18 2.2 1.43–3.39 1.31 0.92–1.86
Adjusteda 1.08 0.80–1.46 1.56 0.96–2.52 0.94 0.64–1.37
Adjusted for clinic systolic BP and other factorsa 1.18 0.84–1.66 1.57 0.90–2.75 1.13 0.76–1.69
BP=blood pressure; ESRD=end-stage renal disease; s.d.=standard deviation.
Hazard ratios are reported for 1 s.d. change in BP.
aModel was adjusted for age, ethnicity, diabetes mellitus, log protein/creatinine ratio, estimated Modification of Diet in Renal Disease Study glomerular filtration rate, serum
albumin, hemoglobin and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use.
Table 4 | Hazard ratios for renal end points associated with various definitions of dipping
ESRD or death ESRD Total mortality
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Asleep minus awake ambulatory systolic BP 1.31 1.04–1.64 1.27 0.92–1.76 1.44 1.10–1.87
Asleep/awake ambulatory systolic BP ratio 1.36 1.09–1.71 1.34 0.97–1.85 1.48 1.13–1.93
Night minus day ambulatory systolic BP 1.47 1.17–1.85 1.48 1.08–2.04 1.48 1.12–1.94
Night/day ambulatory systolic BP ratio 1.52 1.21–1.92 1.53 1.12–2.11 1.54 1.17–2.02
BP=blood pressure; ESRD=end-stage renal disease.
Hazard ratios are reported for 1 s.d. change in dipping systolic pressure (s.d.’s are shown in Table 1).
Bold numerals indicate those hazard ratios that were statistically significant.
Table 5 | Hazard ratios for renal end points associated with night/day systolic ABP ratio
ESRD or death ESRD Total mortality
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Hazard
ratio
95% confidence
interval
Night/day ambulatory systolic BP ratio 1.52 1.21–1.92 1.53 1.12–2.11 1.54 1.17–2.02
Dipping adjusted for systolic ambulatory BP 1.28 1.005–1.63 1.04 0.73–1.47 1.42 1.06–1.90
Unadjusted day ambulatory BP 1.77 1.38–2.26 3.06 2.10–4.45 1.32 0.98–1.76
Unadjusted night ambulatory BP 1.86 1.49–2.33 2.53 1.86–3.44 1.5 1.15–1.96
Day ambulatory BP adjusted for night ambulatory BP 1.06 0.68–1.64 2.03 1.08–3.82 0.74 0.43–1.26
Night ambulatory BP adjusted for day ambulatory BP 1.79 1.20–2.67 1.55 0.90–2.66 1.90 1.17–3.11
BP=blood pressure; ESRD=end-stage renal disease.
Hazard ratios are reported for 1 s.d. change in dipping systolic pressure (s.d.’s are shown in Table 1).
Bold numerals indicate those hazard ratios that were statistically significant.
43210
Years
Cu
m
ul
at
ive
 h
az
ar
d 
of
 E
SR
D
Ambulatory systolic
BP N/D ratio < 0.93
5
0.4
0.3
0.2
0.1
0.0
Ambulatory systolic
BP N/D ratio 0.93–0.99
Ambulatory systolic
BP N/D ratio > 0.99
Log rank P = 0.016
Figure 2 | Association of dipping and ESRD events: Night/day
systolic ambulatory BP was divided into three tertiles. Increasing
severity of non-dipping was associated with increasing ESRD events
(P¼ 0.016, log-rank test).
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outcomes in patients with essential hypertension.12 In 80
patients on chronic hemodialysis, Liu et al.13 have shown that
non-dipping was associated with an HR of 2.5 for
cardiovascular events and 9.6 for cardiovascular death.
Tripepi et al.14 have shown that in hemodialysis patients
without diabetes mellitus and cardiovascular events, the
night/day ratio is a predictor of total mortality and
cardiovascular mortality. Although no study has examined
the relationship between dipping and ESRD outcomes in
non-dialysis CKD patients, an association with more rapid
progression of kidney disease has been noted.15
Interestingly, we found day BP to be a stronger predictor of
ESRD, whereas the night systolic BP to be a stronger predictor
of deaths. The association of day BP, rather than night BP, in
predicting ESRD outcomes has not been reported previously.
The association of night BP with deaths is consistent with
findings of Amar et al.,16 who found that nocturnal BP was
linked to mortality in French hemodialysis patients.
The stronger correlation of ambulatory BP, rather than
clinic BP, with hard outcomes may be owing to several
reasons. First, timing of the administration of antihyperten-
sive drugs can be variable, and multiple BP measurements
over the course of the day, as done with ambulatory BP
monitoring, can therefore average out the troughs and peaks
in BP swings, which clinic BP recordings are unable to do.17
Second, clinic BPs are influenced by the white coat effect –
elevated BP only in the office setting – which is removed with
ambulatory BP monitoring. This misclassification as a result
of clinic BP monitoring may contribute to poorer prediction
of renal outcomes with clinic BP monitoring. Indeed, in this
study, we found that in patients with normal systolic BP by
ambulatory monitoring had a much lower event rate
compared to those who had elevated ambulatory systolic BP.
There are some limitations that need to be noted. Our
study was largely limited to older men with concomitant
illnesses and a single center. We also excluded patients with
morbid obesity and atrial fibrillation owing to difficulties
with accurate BP assessment in this population. Whether the
same results would hold in women and younger people and
over several centers needs further study. There are also no
data available that show superiority of outcomes when
ambulatory BPs, rather than clinic BPs, are used to guide
therapy. Reproducibility of the dipping phenomenon is poor
and ideally two measurements of ambulatory monitoring
would be superior to evaluate the impact of the dipping
phenomenon on renal outcomes.18 Finally, ambulatory BP
did not add to the prediction of hard outcomes when
adjustment of other risk factors for CKD progression was
made.
In conclusion, ambulatory BP monitoring in patients with
CKD adds to our ability to predict hard end points, over and
above clinic BPs. The dipping phenomenon is also useful,
especially for predicting total mortality, even after accounting
for 24-h ambulatory systolic BP. These results demonstrate
that ambulatory BP monitoring can complement assessment
of ESRD risk when added to clinic BP monitoring using
standard procedures in patients with CKD.
MATERIALS AND METHODS
Consecutive patients were recruited from the Renal and a General
Medicine Clinic at the Indianapolis Veterans Affairs Hospital
between November 2000 and June 2002 if they were X18 years of
age with an estimated glomerular filtration rate o60 ml/min/
1.73 m2 by the abbreviated four-component, Modification of Diet in
Renal Disease formula or glomerular filtration rate o90 ml/min/
1.73 m2 and urine albumin/urine creatinine ratio of 430 mg/g.19
Patients were excluded for body mass index 440 kg/m2, acute renal
failure, receiving renal replacement therapy, atrial fibrillation, or
change in their antihypertensive regimens within 2 weeks of study
enrollment.
The Institutional Review Board of Indiana University and the
Research and Development Committee of the Richard L Roudebush
Veterans Affairs Medical Center approved this study, and all patients
gave their written, informed consent.
Clinic blood pressures
Standardized clinic BPs were obtained by one nurse trained in BP
measurement.20 Briefly, patients were seated for at least 5 min before
measurements and refrained from smoking or caffeine ingestion for
at least 30 min. The patient’s arm was kept at the heart level during
the measurement, and using an appropriate-sized cuff, three
measurements, via the Omron 412C semiautomatic BP monitor
(Omron Healthcare, Vernon Hills, IL, USA), were obtained in both
arms. At least 30 s elapsed between BP measurements. For each
individual patient, the average BP from each arm was calculated.
The higher of the two averages was defined as the patient’s
standardized BP. The arm with the higher BP was used to determine
the ambulatory BP. Clinic BPs were averaged over two visits: one was
an afternoon visit concurrent to the ambulatory BP visit and a
second that typically was in the morning 1 week later.
Ambulatory blood pressures
The patients underwent 24 h ambulatory BP monitoring with the
Spacelabs 90207 monitor (Spacelabs Inc., Redmond, WA, USA), a
monitor that has been validated by the British Hypertension Society
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Figure 3 | Twenty-four hours ambulatory systolic BPs were
divided into three categories, o130, 130 to o160, and 160 mm
Hg or more, reflecting nationally recommended levels of control,
and two degrees of poor control. Three of the 76 (4%) patients in
the well-controlled category had ESRD, 23/88 (26%) patients in 130 to
o160 mm Hg had ESRD, and 8/11 (73%) in the 160 mm Hg or more
category had ESRD (Po0.0001 by log-rank test).
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and the Association for the Advancement of Medical Instrumenta-
tion. The monitor recorded BPs every 20 min during the day
(0600–2200) and every 30 min at night (2200–0600). These periods
were also used to define night and day BP averages. The patients
recorded their sleep and wake times during the ambulatory BP
monitoring. Ambulatory BP monitoring was considered adequate if
14 systolic and diastolic measurements were obtained during the day
and seven during the night based on the guidelines of the European
Society of Hypertension.21 Dipping was also calculated by subtract-
ing the awake systolic BP from asleep systolic BP and day systolic
from night systolic BP.22 Therefore, a negative number would reflect
a fall in systolic BP with sleep. The ratio of asleep/awake systolic BP
of o0.9 mm Hg or night/day systolic BP of o0.9 mm Hg was also
evaluated to predict outcomes.
Outcomes. Renal outcomes were defined a priori and included
a composite end point of ESRD or death, whichever occurred first.
ESRD and total mortality were also analyzed as individual
outcomes. The diagnosis of ESRD was confirmed by confirming
the date of first dialysis from the patients’ medical record or the
ESRD medical evidence report form. Patients were censored on the
date that they had the last clinic visit.
Analysis. Cox’s proportional hazards regression was used to
determine the significance and strength of association of factors
associated with renal outcomes. The proportionality assumption
was tested by testing the significance of the time covariate
interaction term. Hazard ratios and 95% confidence intervals were
calculated from the proportional hazards model regression coeffi-
cients and their standard errors for 1 s.d. change in each BP. As all
BPs were obtained in the same population, the HRs were not
adjusted for the comparisons. The independent effect of ambulatory
systolic BP was tested by including the clinic systolic BPs in the
model. To further test the robustness of this finding, we adjusted the
HRs for other confounders of ESRD, which were ascertained from
studies performed in similar population and included age, ethnicity
(black vs non-black), diabetes mellitus, log urine protein/creatinine
ratio, estimated glomerular filtration rate, serum albumin and
hemoglobin, and the use of angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers.23 Kaplan–Meier survival
analyses were performed after stratification by clinic systolic BP.
Ambulatory systolic BP was tested as a factor within each stratum by
pairwise comparison using the log-rank test. Ambulatory awake
systolic BP of o130 mm Hg was defined as well-controlled BP.24
Significance was set at for a two-sided P- value of o0.05. All
analyses were performed by SPSS for Windows version 13.0 (SPSS
Inc., Chicago, IL, USA).
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